期刊: LANCET ONCOLOGY, 2023; 24 (5)
Increasing evidence suggests that some immunotherapy dosing regimens for patients with advanced cancer could result in overtreatment. Given the high c......
期刊: LANCET ONCOLOGY, 2023; 24 (6)
Background Adding CDK4/6 inhibitor dalpiciclib to fulvestrant significantly prolonged progression-free survival in patients with hormone receptor-posi......